These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 28504893)

  • 1. Dual inhibitors of cholinesterases and monoamine oxidases for Alzheimer's disease.
    Knez D; Sova M; Košak U; Gobec S
    Future Med Chem; 2017 May; 9(8):811-832. PubMed ID: 28504893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
    Reis J; Cagide F; Valencia ME; Teixeira J; Bagetta D; Pérez C; Uriarte E; Oliveira PJ; Ortuso F; Alcaro S; Rodríguez-Franco MI; Borges F
    Eur J Med Chem; 2018 Oct; 158():781-800. PubMed ID: 30245401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids.
    Sun Y; Chen J; Chen X; Huang L; Li X
    Bioorg Med Chem; 2013 Dec; 21(23):7406-17. PubMed ID: 24128814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging therapeutic potentials of dual-acting MAO and AChE inhibitors in Alzheimer's and Parkinson's diseases.
    Mathew B; Parambi DGT; Mathew GE; Uddin MS; Inasu ST; Kim H; Marathakam A; Unnikrishnan MK; Carradori S
    Arch Pharm (Weinheim); 2019 Nov; 352(11):e1900177. PubMed ID: 31478569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual functional cholinesterase and MAO inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of homoisoflavonoid derivatives.
    Wang Y; Sun Y; Guo Y; Wang Z; Huang L; Li X
    J Enzyme Inhib Med Chem; 2016; 31(3):389-97. PubMed ID: 25798687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review on flavonoid-based scaffolds as multi-target-directed ligands (MTDLs) for Alzheimer's disease.
    Jalili-Baleh L; Babaei E; Abdpour S; Nasir Abbas Bukhari S; Foroumadi A; Ramazani A; Sharifzadeh M; Abdollahi M; Khoobi M
    Eur J Med Chem; 2018 May; 152():570-589. PubMed ID: 29763806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of 3-arylcoumarins as potential anti-Alzheimer's disease agents.
    Yang J; Zhang P; Hu Y; Liu T; Sun J; Wang X
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):651-656. PubMed ID: 30746966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.
    Bautista-Aguilera OM; Esteban G; Bolea I; Nikolic K; Agbaba D; Moraleda I; Iriepa I; Samadi A; Soriano E; Unzeta M; Marco-Contelles J
    Eur J Med Chem; 2014 Mar; 75():82-95. PubMed ID: 24530494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo Biological Evaluation of Newly Tacrine-Selegiline Hybrids as Multi-Target Inhibitors of Cholinesterases and Monoamine Oxidases for Alzheimer's Disease.
    Huang ST; Luo JC; Zhong GH; Teng LP; Yang CY; Tang CL; Jing L; Zhou ZB; Liu J; Jiang N
    Drug Des Devel Ther; 2024; 18():133-159. PubMed ID: 38283137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: Potential multifunctional anti-Alzheimer's agents.
    Košak U; Knez D; Coquelle N; Brus B; Pišlar A; Nachon F; Brazzolotto X; Kos J; Colletier JP; Gobec S
    Bioorg Med Chem; 2017 Jan; 25(2):633-645. PubMed ID: 27908752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine.
    Samadi A; de los Ríos C; Bolea I; Chioua M; Iriepa I; Moraleda I; Bartolini M; Andrisano V; Gálvez E; Valderas C; Unzeta M; Marco-Contelles J
    Eur J Med Chem; 2012 Jun; 52():251-62. PubMed ID: 22503231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-Based Design and Optimization of Multitarget-Directed 2H-Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases.
    Farina R; Pisani L; Catto M; Nicolotti O; Gadaleta D; Denora N; Soto-Otero R; Mendez-Alvarez E; Passos CS; Muncipinto G; Altomare CD; Nurisso A; Carrupt PA; Carotti A
    J Med Chem; 2015 Jul; 58(14):5561-78. PubMed ID: 26107513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
    Li Y; Qiang X; Luo L; Yang X; Xiao G; Zheng Y; Cao Z; Sang Z; Su F; Deng Y
    Bioorg Med Chem; 2017 Jan; 25(2):714-726. PubMed ID: 27923535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and β-amyloid in ageing and Alzheimer's disease.
    Weinreb O; Amit T; Bar-Am O; Youdim MB
    Br J Pharmacol; 2016 Jul; 173(13):2080-94. PubMed ID: 26332830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and pharmacological evaluation of donepezil-based agents as new cholinesterase/monoamine oxidase inhibitors for the potential application against Alzheimer's disease.
    Li F; Wang ZM; Wu JJ; Wang J; Xie SS; Lan JS; Xu W; Kong LY; Wang XB
    J Enzyme Inhib Med Chem; 2016; 31(sup3):41-53. PubMed ID: 27384289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel propargylamine-based inhibitors of cholinesterases and monoamine oxidases: Synthesis, biological evaluation and docking study.
    Krátký M; Vu QA; Štěpánková Š; Maruca A; Silva TB; Ambrož M; Pflégr V; Rocca R; Svrčková K; Alcaro S; Borges F; Vinšová J
    Bioorg Chem; 2021 Nov; 116():105301. PubMed ID: 34492558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational design of new multitarget histamine H
    Łażewska D; Bajda M; Kaleta M; Zaręba P; Doroz-Płonka A; Siwek A; Alachkar A; Mogilski S; Saad A; Kuder K; Olejarz-Maciej A; Godyń J; Stary D; Sudoł S; Więcek M; Latacz G; Walczak M; Handzlik J; Sadek B; Malawska B; Kieć-Kononowicz K
    Eur J Med Chem; 2020 Dec; 207():112743. PubMed ID: 32882609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donepezil + chromone + melatonin hybrids as promising agents for Alzheimer's disease therapy.
    Pachón-Angona I; Refouvelet B; Andrýs R; Martin H; Luzet V; Iriepa I; Moraleda I; Diez-Iriepa D; Oset-Gasque MJ; Marco-Contelles J; Musilek K; Ismaili L
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):479-489. PubMed ID: 30712420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contilisant, a Tetratarget Small Molecule for Alzheimer's Disease Therapy Combining Cholinesterase, Monoamine Oxidase Inhibition, and H3R Antagonism with S1R Agonism Profile.
    Bautista-Aguilera ÓM; Budni J; Mina F; Medeiros EB; Deuther-Conrad W; Entrena JM; Moraleda I; Iriepa I; López-Muñoz F; Marco-Contelles J
    J Med Chem; 2018 Aug; 61(15):6937-6943. PubMed ID: 29969030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual Monoamine Oxidase and Cholinesterase Inhibitors with Different Heterocyclic Scaffolds.
    Gulcan HO; Orhan IE
    Curr Top Med Chem; 2021; 21(30):2752-2765. PubMed ID: 34477521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.